A peptide manufacturing facility in India has two very different halves. The first makes the drug substance: building the peptide chain, purifying it on large chromatography columns and freeze-drying it, a process that uses enormous volumes of solvent. The second turns it into a sterile injectable, filled into vials, cartridges or pens under aseptic conditions. Most of the capital, and most of the risk, sits in solvent handling on one side and sterility on the other.
Why is everyone talking about peptides?
Because of one molecule. Semaglutide, the GLP-1 drug sold globally for diabetes and weight loss, lost patent protection in India on 20 March 2026. More than 40 Indian companies were reported to be preparing launches, with over 50 brands expected through the year, and generic prices were expected to land 50 to 60% below the innovator’s. One company alone announced plans for 12 million pens in its first year.
Patents in the US and Europe run into the 2030s, so the Indian market is the first big test, and export markets will follow. That is pushing companies to secure peptide capacity now, and peptide capacity does not appear overnight.
How is a peptide made?
There are two broad routes. Many generic makers use solid-phase peptide synthesis, building the chain one amino acid at a time on resin beads. Others use a recombinant route, where engineered cells make the peptide backbone, followed by chemical steps to finish the molecule. Either way, the crude product then goes through preparative chromatography to reach the purity regulators expect, and is freeze-dried into a stable powder.
The sterile part comes next: compounding the solution, filtering it, and filling it into the final container, often a prefilled pen.
What does each area need?
| Area | What Happens There | What the Building Must Handle |
|---|---|---|
| Peptide Synthesis | Chain assembly in synthesis reactors | Large solvent use, flameproof design, scrubbers, solvent recovery |
| Purification | Preparative HPLC on large columns | Very high solvent volumes, hazardous area design, solvent storage under PESO licensing |
| Lyophilisation | Freeze-drying the purified peptide | Heavy power, chilled water, clean environment |
| QC Laboratory | Purity, impurities, identity and potency testing | Analytical instruments, stable power, data integrity controls |
| Aseptic Fill-Finish | Filling vials, cartridges, or pens | Classified cleanrooms, isolators or barrier systems, validated HVAC |
| Device Assembly and Packing | Assembling pens, labelling, and serialisation | Clean controlled space, line clearance controls |
Where do peptide projects run into trouble?
Solvents. Peptide synthesis and purification can use hundreds of litres of solvent per kilogram of product. That drives solvent storage limits, recovery systems, effluent treatment and pollution control approvals, and it is often the factor that decides whether a site is usable at all.
Sterility. Fill-finish for injectables is unforgiving. Cleanroom grades, aseptic process simulations and environmental monitoring all have to hold up to inspection, especially for export markets.
Speed. Building both halves from scratch takes years. That is why many companies split the work: in-house drug substance, partner fill-finish, or the reverse, while they build out.
What should you check before committing to a site?
- Solvent storage capacity and PESO licensing limits
- Solvent recovery and effluent treatment for peptide chemistry
- Flameproof and hazardous area design for synthesis and purification
- Power and chilled water for lyophilisers
- Cleanroom space for aseptic fill, with room for isolators
- Separation between chemical synthesis and sterile areas
- Space to add a second line as demand grows
Where does a GMP-ready campus help?
Peptide facilities combine the hardest parts of chemistry plants and sterile injectable plants. Starting on a campus that already runs power, utilities, effluent treatment, gas detection and environmental monitoring takes a large slice of time and risk out of the project.
NQF Hubs (NXT QST FWD) provides GMP-ready manufacturing modules, built-to-suit facilities and turnkey build-outs with GMP qualification support, as set out on its Solutions page. Our guides to high-potency containment and revised Schedule M compliance options cover related decisions.
Frequently asked questions
When did semaglutide go generic in India?
Semaglutide’s patent protection in India ended on 20 March 2026, and many Indian companies launched generic versions soon after. Patents in the US and Europe run into the 2030s.
How are generic peptides like semaglutide made?
Either by solid-phase peptide synthesis, building the chain chemically, or by a recombinant route followed by chemical modification. Both need large-scale purification and freeze-drying.
Why do peptide plants need so much solvent?
Synthesis and preparative chromatography both use large volumes of solvent per kilogram of product. That drives storage, recovery, effluent treatment and safety design.
What does sterile fill-finish for pens need?
Classified cleanrooms, isolators or barrier systems, validated HVAC, environmental monitoring and aseptic process simulations, followed by controlled pen assembly and packing.
Building peptide or injectable capacity? Talk to NQF Hubs about GMP-ready and built-to-suit space. Get in touch
6. External sources cited
- Business Today, “India’s weight loss drug moment: What happens when semaglutide goes generic” (20 Mar 2026): https://www.businesstoday.in/amp/industry/pharma/story/indias-weight-loss-drug-moment-what-happens-when-semaglutide-goes-generic-521612-2026-03-20
- Business Today, “Novo further cuts semaglutide prices as generics enter India” (31 Mar 2026): https://www.businesstoday.in/amp/industry/pharma/story/novo-further-cuts-semaglutide-prices-as-generics-enter-india-523336-2026-03-31/
- WHO, TRS 1019 Annex 3, GMP guidelines on validation: https://www.who.int/publications/m/item/trs1019-annex3